Smoking cessation pill Chantix just got a reprieve from the Food and Drug Administration: The Pfizer drug no longer needs to carry a black box warning label noting that users are at risk for serious side effects like suicidal thoughts and hostility.

Pfizer has been battling the dreadful publicity around Chantix’s potential neuropsychiatric side effects ever since the drug was approved about a decade ago. Sales, which were expected to place Chantix in blockbuster status, have plateaued in the years since approval — thanks, in part, to a spate of lawsuits that claimed the drug caused violent or suicidal behavior.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Stat plus. You have the nerve to give me part of an article for my globe subscription and send me to a pay wall!. This is worse than reporting on tweets, which is pathetic journalism. I’ll be cancelling my globe subscription Monday.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy